Episode

E137: Obexelimab in IgG4-RD (INDIGO)

Podcast: The Evidence Based Rheumatology Podcast
Published: Jun 29, 2026
Duration seconds: 936
Processing state: not_requested
Canonical source: https://msputman.podbean.com/e/e137-obexelimab-in-igg4-rd-indigo/
Audio: https://mcdn.podbean.com/mf/web/93p3tikzrv3tcmvs/e137.mp3
JSON: /v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e137-obexelimab-in-igg4-rd-indigo
Markdown: /podcast/the-evidence-based-rheumatology-podcast-1130175/e137-obexelimab-in-igg4-rd-indigo.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e137-obexelimab-in-igg4-rd-indigo/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e137-obexelimab-in-igg4-rd-indigo.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Another day, another B cell drug. This one adds an interesting option for IgG4-RD, offering a "maybe less efficacious maybe less toxic" pathway. I could see folks being excited for this, especially in a disease where non-scary-manifestations are relatively common. Also, check out boardsbank.com! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2601337